Invention Grant
- Patent Title: Antibodies that are capable of specifically binding tissue factor pathway inhibitor
- Patent Title (中): 能够特异性结合组织因子途径抑制剂的抗体
-
Application No.: US13780631Application Date: 2013-02-28
-
Publication No.: US09228022B2Publication Date: 2016-01-05
- Inventor: Ida Hilden , Jes Thorn Clausen , Lars Christian Petersen , Brit Binow Soerensen , Helle Heibroch Petersen , Anders Svensson
- Applicant: Novo Nordisk A/S
- Applicant Address: DK Bagsvaerd
- Assignee: Novo Nordisk A/S
- Current Assignee: Novo Nordisk A/S
- Current Assignee Address: DK Bagsvaerd
- Agent Jianjie Hu
- Priority: EP10167911 20100630; EP11160763 20110401
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K16/38
Abstract:
The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralizing free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
Public/Granted literature
- US20130253173A1 Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor Public/Granted day:2013-09-26
Information query
